FDA approves more broadly protective meningococcal vaccine
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
GlaxoSmithKline share price extends post-Q3 results rally. Jumps 36% in two days
GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...
MyJoyOnline9h
Africa-specific research key to tackling continent’s health challenges, says GSK’s Dr. Juliet Addo
Dr. Juliet Addo, Academic Engagement Director for Ghana and Head of the Africa Open Lab at GSK, has reaffirmed the importance ...
European shares tipped to soar as US investors pile in - experts reveal the cheap stocks they would buy
Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...
European stocks are set to soar as US investors pile in. Here the world's top experts reveal the dirt-cheap stocks that could make YOU a packet
Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...
BioPharma Dive12h
GSK’s 5-in-1 meningococcal shot wins FDA approval
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
Daily12h
FDA Approves GSK's Pentavalent Meningococcal Vaccine
The US Food and Drug Administration (FDA) has approved GSK’s pentavalent meningococcal vaccine, Penmenvy, for children and ...
STAT13h
Pharmalittle: We’re reading about the impact of HHS firings, a GSK vaccine approval, and more
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
cnbctv1814h
GSK Pharma shares surge 29% in two days, driven by strong Q3; brokerages bullish
Shares of GlaxoSmithKline Pharmaceuticals Ltd ended at ₹2,608, up by ₹275.75, or 11.82%, on the BSE. Brokerage firms, ...
GSK Pharma shares jump 15%, extend gains to 2nd straight day after strong Q3 results
GSK Pharma had reported a consolidated net profit of Rs 230 crore for Q3 FY25. This marks a significant surge of nearly 400 ...
Medindia20h
Benign Prostatic Hyperplasia Surgical Treatment Market to Hit USD 17.19 Billion by 2030 with 5.3% CAGR | MarketsandMarkets™
The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...